A pharmacokinetics study published in Frontiers in Pharmacology found an average intravenous elimination half-life (t1/2) of 15.2 minutes in rats, with the intramuscular peak plasma concentration reached at 3 minutes post-injection
A 12-week randomized trial demonstrated: Average weight loss of 2.6 kg in AOD-9604 group (1 mg/day) versus 0.8 kg in placebo group Preferential reduction in abdominal and visceral fat deposits No adverse effects on carbohydrate metabolism or insulin sensitivity Non-dose-dependent effects, with higher doses (10 mg/day) producing less weight loss than lower doses However, a subsequent 24-week Phase III trial with 502 subjects incorporating intensive diet and exercise showed no statistically significant weight loss compared to placebo, leading to development termination in 2007
It also depends on any swallowing or digestion problems
By understanding these differences, medical professionals can make more informed decisions about which solution best fits a specific medical application
Missing a day occasionally wont ruin your progressbut consistency matters
Grip strength increased by approximately 60% when the compound was combined with rigorous exercise training, compared to about 25% improvement from either exercise or treatment alone
